Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P DesJardins

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Drug Information Journal|December 13, 1977
Device information and government regulationsJ P Desjardins
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivoJ P Desjardins, P L Iversen
The Journal of Bone and Joint Surgery. British Volume|February 1, 1974
The femoral neck in Legg-Perthes' disease. Its relationship to epiphysial change and its importance in early prognosisJ Robichon, J P Desjardins, M Koch, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|May 1, 1972
Functional anatomy of the ankle joint and its relationship to ankle injuriesJ Robichon, J Pegington, V B Moonje, et al.
Canadian Medical Association Journal|March 4, 1978
Dermatologic problems in amputeesJ P DesGroseilliers, J P DesJardins, J P Germain, et al.
Cancer Letters|December 16, 1998
Transcriptional activity of quinone methides derived from the tumor promoter butylated hydroxytoluene in HepG2 cellsJ P Desjardins, S E Beard, J E Mapoles, et al.
Pharmaceutical Research|August 26, 1998
In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugsR Joshi, V Arora, J P Desjardins, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1996
Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injectionsJ P Desjardins, B S Sproat, B Beijer, et al.
Anti-Cancer Drugs|April 6, 2001
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing miceJ P Desjardins, E A Abbott, D L Emerson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecanD L Emerson, R Bendele, E Brown, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Drug Information Journal|December 13, 1977
Device information and government regulationsJ P Desjardins
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivoJ P Desjardins, P L Iversen
The Journal of Bone and Joint Surgery. British Volume|February 1, 1974
The femoral neck in Legg-Perthes' disease. Its relationship to epiphysial change and its importance in early prognosisJ Robichon, J P Desjardins, M Koch, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|May 1, 1972
Functional anatomy of the ankle joint and its relationship to ankle injuriesJ Robichon, J Pegington, V B Moonje, et al.
Canadian Medical Association Journal|March 4, 1978
Dermatologic problems in amputeesJ P DesGroseilliers, J P DesJardins, J P Germain, et al.
Cancer Letters|December 16, 1998
Transcriptional activity of quinone methides derived from the tumor promoter butylated hydroxytoluene in HepG2 cellsJ P Desjardins, S E Beard, J E Mapoles, et al.
Pharmaceutical Research|August 26, 1998
In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugsR Joshi, V Arora, J P Desjardins, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1996
Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injectionsJ P Desjardins, B S Sproat, B Beijer, et al.
Anti-Cancer Drugs|April 6, 2001
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing miceJ P Desjardins, E A Abbott, D L Emerson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecanD L Emerson, R Bendele, E Brown, et al.
Pageof 1